Colleen S Kraft, MD

Assistant Professor of Medicine

Emory University School of Medicine

Associate Professor of Pathology & Laboratory Medicine

Department of Pathology at Emory University School of Medicine

Program Director, Medical Microbiology

Medical Director, Microbiology Laboratory

Education

  • BA, Taylor University, 1998
  • MD, Indiana University School of Medicine, 2002
  • MSc, Emory University, 2013

Biography

Colleen S. Kraft, MD, has a secondary appointment with the Department of Medicine Division of Infectious Diseases. Her primary appointment is an assistant professor in the Department of Pathology at Emory University School of Medicine. She is also the director of the Clinical Virology Research Laboratory which is a university service center that performs molecular testing.

Research Interests

Fecal microbiota transplant

Fecal microbiota transplant (FMT) is a method of transferring donor feces by either colonoscopy or nasogastric route to recipients with C. difficile diarrhea. This has proven in the literature to have durable success as a therapy. At Emory University, we have a large solid organ transplant patient population. Under FDA enforcement discretion, we performed fecal microbiota transplant on 2 patients with solid organ transplant. We were the first to show that solid organ transplant patients could undergo FMT with minimal side effects. Subsequent manuscripts have confirmed our initial observations that this is safe in this population. Other publications related to our work as a fecal transplant at Emory University can be found at www.medicine.emory.edu/fecaltransplant. 

Clinical care of Ebola virus disease

I was one of the physician leaders in the effort at Emory Hospital to receive and care for patients who had contracted Ebola virus disease in West Africa. Since December 2013, the largest outbreak of Ebola virus disease took place, and healthcare workers were particularly vulnerable to acquisition of this viral infection. Emory University Hospital has had a Serious Communicable Diseases unit since 2001, and I have been a part of the semi-annual drills since 2010. We received our first patient on August 2, 2014, with 3 subsequent patients being cared for in this highly specialized unit. Based on our clinical observations, our group has published numerous papers regarding the clinical care of patients with Ebola virus disease. I was lead author on the paper describing the initial hospital course of our critically ill patient, and our experience with 2 experimental drugs for Ebola virus disease, TKM-100802 and convalescent plasma

Associations

  • American Federation for Medical Research
  • Infectious Disease Society of America
  • HIV Medicine Association
  • American Society for Microbiology
  • Pan-American Society for Clinical Virology

Publications